A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Myeloproliferative Neoplasms
DRUG: INCA033989|DRUG: Ruxolitinib
Number of participants with Dose Limiting Toxicities (DLTs), Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol., Up to 28 days|Number of participants with Treatment-emergent Adverse Events (TEAEs), Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug, including those leading to dose modification or discontinuation., Up to 3 years and 60 days
Participants with MF: Response using the revised IWG-MRT and ELN response criteria for MF, Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria., Up to 3 years and 60 days|Participants With MF: Percentage of participants achieving spleen volume reduction as defined in the protocol, Defined as percentage of participants with a protocol defined Spleen Volume Reduction., Up to 24 weeks|Participants with symptomatic anemia: Anemia Response as defined in the protocol, Anemia Response as defined by the protocol., Up to 24 weeks|Participants with ET: Response using the revised IWG-MRT and ELN response criteria for ET, Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria., Up to 3 years and 60 days|Incidence of AEs, ECGs, vital signs, and clinical laboratory evaluation, To evaluate the safety of INCA033989., Up to 3 years and 60 days|Percentage of participants achieving ≥ 50% reduction from baseline in total symptom score (TSS), Defined as the percentage of participants achieving ≥ 50% reduction from baseline in TSS., Week 12 and Week 24|Mean change from baseline in TSS, Mean change in TSS from baseline., Week 12 and Week 24|Mean change in disease-related allele burden, Mean change from baseline in disease-related variant allele frequency quantified by targeted NGS and evaluated with myeloid and lymphoid proportion in blood., Up to 3 years and 60 days|Pharmacokinetics Parameter: Cmax of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as maximum observed plasma concentration of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: Tmax of INCA033989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the time to reach the maximum plasma concentration of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: Cmin of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the minimum observed plasma concentration of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: AUC(0-t) of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the area under the concentration-time curve up to the last measurable concentration of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: AUC 0-∞ of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the area under the concentration-time curve from 0 to infinity of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: CL/F of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the apparent oral dose clearance of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: Vz/F of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the apparent oral dose volume of distribution of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days|Pharmacokinetics Parameter: t1/2 of INCA33989 alone or for the combination of INCA033989 with ruxolitinib, Defined as the apparent terminal phase disposition half-life of INCA33989 alone or for the combination of INCA033989 with ruxolitinib., Up to 3 years and 60 days
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.